[msk-node-teaser: 18818 right]Gynecologic oncologist Oliver Zivanovic describes the growing program at Memorial Sloan Kettering Cancer Center to assess heated intraperitoneal chemotherapy (HIPEC) to treat ovarian cancer in women undergoing cytoreductive surgery (performed to remove cancerous tissue from the abdominal cavity). Very few centers in the country are offering this new approach under the umbrella of controlled clinical trials. Surgery followed by chemotherapy is the standard treatment for ovarian cancer. Using HIPEC, surgeons are able to give chemotherapy in the controlled environment of the operating room at higher doses than intravenous treatment, exposing the cancer cells directly to anticancer drugs. It is believed that heating the chemotherapy may make it better able to penetrate and kill cancer cells. Patients undergo cytoreductive surgery; intraperitoneal tubes connected to the HIPEC machine are then placed in the abdominal cavity; the abdomen is closed temporarily. The heated chemotherapy is perfused into the abdomen for 90 to 120 minutes; the tubes are removed, the abdomen irrigated, and the incision closed in a standard fashion. HIPEC has been shown to be safe and does not affect postoperative standard treatment.